Mirtazapine
- Generic Name
- Mirtazapine
- Brand Names
- Remeron
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N3
- CAS Number
- 85650-52-8
- Unique Ingredient Identifier
- A051Q2099Q
- Background
Mirtazapine is a tetracyclic piperazino-azepine antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder. The effects of this drug may be observed as early ...
- Indication
This drug is indicated for the treatment of major depressive disorder and its associated symptoms.
...
- Associated Conditions
- Cancer Pain, Depression, Fibromyalgia, Generalized Anxiety Disorder, Hot Flashes, Insomnia, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Persistent Depressive Disorder (Dysthymia), Post Operative Nausea and Vomiting (PONV), Poststroke depression, Sleep disorders and disturbances, Substance Abuse Disorders, Tension Headache
- Associated Therapies
- -
The Measurement-based Care in Patients With Depressive Disorder: A Randomized Controlled Trial
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Capital Medical University
- Target Recruit Count
- 164
- Registration Number
- NCT02191124
- Locations
- 🇨🇳
Beijing Anding Hospital, Beijing, Beijing, China
Double-blind Pilot Trial of Mirtazapine for the Treatment of Co-occurring AD/MDD.
- Conditions
- Interventions
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 16
- Registration Number
- NCT02185131
- Locations
- 🇺🇸
Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States
Interpersonal Psychotherapy for Treatment Resistant Depression
- Conditions
- Interventions
- Other: IPT+ antidepressant drugsDrug: fluoxetineDrug: sertralineDrug: paroxetineDrug: CitalopramDrug: escitalopramDrug: fluvoxamineDrug: VenlafaxineDrug: DuloxetineDrug: BupropionDrug: LithiumDrug: RisperidoneDrug: tranylcypromineDrug: ImipramineDrug: amitriptylineDrug: ClomipramineDrug: nortriptylineDrug: trazodoneDrug: MirtazapineDrug: sulpiride
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2013-07-11
- Lead Sponsor
- Hospital de Clinicas de Porto Alegre
- Target Recruit Count
- 74
- Registration Number
- NCT01896349
- Locations
- 🇧🇷
Federal University of Rio Grande do Sul / Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil
Mirtazapine for the Treatment of Methamphetamine Dependence Among MSM (M2.0)
- First Posted Date
- 2013-06-28
- Last Posted Date
- 2018-03-13
- Lead Sponsor
- Phillip Coffin, MD, MIA
- Target Recruit Count
- 120
- Registration Number
- NCT01888835
- Locations
- 🇺🇸
Substance Use Research Unit, San Francisco, California, United States
Mirtazapine for Sleep Disorders in Alzheimer's Disease
- First Posted Date
- 2013-06-04
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- Brasilia University Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT01867775
- Locations
- 🇧🇷
Brasilia University, Brasilia, Distrito Federal, Brazil
Algorithm Guided Treatment Strategies for Major Depressive Disorder
- Conditions
- Interventions
- First Posted Date
- 2013-01-10
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- Shanghai Mental Health Center
- Target Recruit Count
- 1080
- Registration Number
- NCT01764867
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai, China
Pilot Study to Evaluate Individualized Choice of Antidepressants in Patients With Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-11-12
- Last Posted Date
- 2017-03-13
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT01725048
- Locations
- 🇺🇸
University of North Carolina Hospital, Chapel Hill, North Carolina, United States
LEPR Polymorphism Weight Gain by Mirtazapine in Late Life Depression
- First Posted Date
- 2012-05-17
- Last Posted Date
- 2016-04-21
- Lead Sponsor
- Lawson Health Research Institute
- Target Recruit Count
- 19
- Registration Number
- NCT01601002
- Locations
- 🇨🇦
London Health Sciences Centre, London, Ontario, Canada
Mirtazapine in Alzheimer-associated Weight Loss
- Conditions
- First Posted Date
- 2012-01-06
- Last Posted Date
- 2012-01-06
- Lead Sponsor
- Brugmann University Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT01505504
- Locations
- 🇧🇪
CHU Brugmann, Brussels, Belgium
Megestrol Acetate With or Without Mirtazapine in Treating Cancer Patients With Weight Loss or Loss of Appetite
- First Posted Date
- 2011-12-29
- Last Posted Date
- 2014-02-03
- Lead Sponsor
- Washington University School of Medicine
- Registration Number
- NCT01501396
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.